Features of Treatment of Patients Infected with Hepatitis C Virus Genotypes 1 And 4 by Direct-Acting Antiviral Drugs

Abstract

Hepatitis C is an urgent problem today because of the low efficiency and a significant number of side effects of conventional therapy. The problem of the treatment of hepatitis C virus (HCV) genotypes 1 and 4 is particularly acute, as they are the most resistant to traditional treatment regimens. The solution to this problem, apparently, is the use of a relatively new group of direct-acting antiviral drugs (DAAD). This article discusses the various schemes of treatment with these products, their mechanism of action and effectiveness, as well as compares two of the most effective and promising DAAD available on the global market — Harvoni (sofosbuvir/ledipasvir) and Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir). Current guidelines of the European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD) and the Canadian Association for the Study of the Liver (CASL) on the treatment of patients with HCV genotypes 1 and 4 are also compared.